2020 American Society for Neural Therapy and Repair Conference

2020年美国神经治疗与修复学会会议

基本信息

  • 批准号:
    10055563
  • 负责人:
  • 金额:
    $ 2.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-01 至 2022-03-31
  • 项目状态:
    已结题

项目摘要

Neurodegenerative disorders such as Alzheimer's disease (AD), Huntington's disease and Parkinson's disease (PD), acute disorders such as traumatic brain injury, spinal cord injury, and stroke, and neurodevelopmental disorders such as Angelman's Syndrome, Rett Syndrome, and Spinal Muscular Atrophy are amongst a plethora of devastating neurological conditions for which there are little to no treatments. The financial and emotional burden to patients and their families is indescribable; in addition, the cost of care and lost wages is an enormous financial liability for the US economy. The American Society for Neural Therapy and Repair (ASNTR) is a society focused on basic, translational, and clinical aspects of neurological disorders. The ASNTR membership uses cell transplantation, gene therapy, tissue engineering, neuropharmacology, and other cutting-edge technologies to study and treat such disorders. The 2020 annual meeting of ASNTR will be held at Sheraton Sand Key, Clearwater Beach, FL. This locale provides for a very unique and intimate setting which promotes interactions between junior trainees and accomplished investigators, as well as fostering unique collaborations. The 2020 meeting will be focused on new directions in neural repair and therapy in the coming decade, and the challenges of translating new therapies. As such, planned sessions will cover the “Stem Cell Programming”, “Alzheimer's Disease”, a trainee organized “Who, What, Where, and When to Transplant” and “Emerging Neurotechnologies”. We will hold the annual trainee session for all travel award winners and any member that wishes to attend “Taking the Plunge: Pursuing Translational Research Opportunities available at NINDS” that will feature speakers from the Department of Translational Research at NINDS. Moreover, ASNTR is tremendously committed to trainees. The society encourages trainee participation in the governance of ASNTR and focuses on the development of trainees. The purpose of this R13 is to garner travel support for top trainees (selected from submitted abstracts) to offset their costs to attend the 2020 meeting. Moreover, in 2020 we have several trainee-activities planned. We will also hold a data blitz for trainees as well as meet-the-editor luncheons. Moreover, we have planned social events, aimed at furthering the interaction between faculty and trainees. ASNTR has a strong track record of fostering young investigators, and we aim to continue in this trajectory. Although we always pursue all methods available (i.e. approach the biotech industry and private foundations) in order to provide travel support for trainees, support from the NIH is crucial in order for us to continue on our strong training mission.
神经退行性疾病,如阿尔茨海默病(AD)、亨廷顿病和帕金森病 (PD)急性疾病,如创伤性脑损伤、脊髓损伤和中风,以及神经发育 诸如Angelman综合征、Rett综合征和脊髓性肌萎缩症的疾病属于 过多的破坏性神经系统疾病,几乎没有治疗方法。金融和 病人及其家属的情感负担是难以形容的;此外,护理费用和工资损失是 这对美国经济来说是一个巨大的财政负担。美国神经治疗与修复学会 (ASNTR)是一个专注于神经系统疾病的基础,转化和临床方面的协会。的 ASNTR成员使用细胞移植,基因治疗,组织工程,神经药理学, 其他尖端技术来研究和治疗这些疾病。 ASNTR的2020年年会将在佛罗里达州克利尔沃特海滩的喜来登沙礁举行。 提供了一个非常独特和亲密的环境,促进初级学员之间的互动, 有成就的调查人员,以及促进独特的合作。2020年会议将重点关注 未来十年神经修复和治疗的新方向,以及将新的 治疗因此,计划的会议将涵盖“干细胞编程”,“阿尔茨海默病”,一个实习生 组织了“谁,什么,哪里,何时移植”和“新兴神经技术”。办好第 为所有旅行奖获奖者和任何希望参加“冒险: 追求NINDS提供的转化研究机会”,将以来自 NINDS的翻译研究部门。此外,ASNTR对受训人员非常重视。 该协会鼓励学员参与ASNTR的治理,并专注于 实习生此R13的目的是为顶级学员(从提交的 摘要),以抵消其出席2020年会议的费用。此外,在2020年,我们有几个培训活动 计划好了我们还将为学员举办一次数据闪电战,以及与编辑见面的午餐会。而且我们 有计划的社交活动,旨在促进教师和学员之间的互动。ASNTR拥有强大的 我们在培养年轻研究人员方面有着良好的记录,我们的目标是继续沿着这一轨道前进。虽然我们总是 采取一切可用的方法(即接触生物技术行业和私人基金会), 对于受训人员的旅行支持,NIH的支持对于我们继续进行强大的培训至关重要 使命。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kyle Fink其他文献

Kyle Fink的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kyle Fink', 18)}}的其他基金

2019 AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR
2019 年美国神经治疗与修复学会
  • 批准号:
    9762479
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE
MSCS 旨在生产用于治疗亨廷顿病的 BDNF 和基因编辑货物
  • 批准号:
    10595651
  • 财政年份:
    2017
  • 资助金额:
    $ 2.5万
  • 项目类别:
MSCs engineered to produce Brain-Derived Neurotrophic Factor for the Treatment of Huntington's disease
间充质干细胞经过改造可产生脑源性神经营养因子,用于治疗亨廷顿病
  • 批准号:
    9362838
  • 财政年份:
    2017
  • 资助金额:
    $ 2.5万
  • 项目类别:
MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE
MSCS 旨在生产用于治疗亨廷顿病的 BDNF 和基因编辑货物
  • 批准号:
    10443416
  • 财政年份:
    2017
  • 资助金额:
    $ 2.5万
  • 项目类别:
Novel epigenetic targets for silencing the Huntingtons disease mutation
沉默亨廷顿病突变的新表观遗传靶点
  • 批准号:
    8960294
  • 财政年份:
    2014
  • 资助金额:
    $ 2.5万
  • 项目类别:
Novel epigenetic targets for silencing the Huntingtons disease mutation
沉默亨廷顿病突变的新表观遗传靶点
  • 批准号:
    8832937
  • 财政年份:
    2014
  • 资助金额:
    $ 2.5万
  • 项目类别:

相似海外基金

Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
  • 批准号:
    10712647
  • 财政年份:
    2001
  • 资助金额:
    $ 2.5万
  • 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
  • 批准号:
    6247642
  • 财政年份:
    1997
  • 资助金额:
    $ 2.5万
  • 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
  • 批准号:
    3718999
  • 财政年份:
  • 资助金额:
    $ 2.5万
  • 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
  • 批准号:
    465668867
  • 财政年份:
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
  • 批准号:
    3719026
  • 财政年份:
  • 资助金额:
    $ 2.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了